{
  "abstract": "The development of chimeric antigen receptor (CAR) T cell therapies for acute myeloid leukemia (AML) remains challenging, underscoring the need for reliable preclinical models. Although AML cell lines are widely used in CAR-T studies, their ability to reflect clinically relevant antigen expression patterns and functional characteristics of primary AML cells has not been systematically evaluated. We characterized nine AML cell lines (KG-1, HL-60, Kasumi-1, OCI-AML2, OCI-AML5, THP-1, U-937, MV4-11, and MOLM-13) as targets for in vitro CAR-T studies. We assessed the expression of established CAR-T target antigens (e.g., CLL1, CD33), cell lines similarity to minimal residual disease (MRD) cells and matched healthy monocytes from 161 AML patients, the expression of emerging AML-associated antigens (Siglec-6, CSF1R, and CD70), growth behavior, and susceptibility to non-specific killing by non-transduced T cells. AML cell lines demonstrated substantial heterogeneity in antigen expression with several cell lines showing antigen densities exceeding those observed in AML blasts. Several widely used lines, including U-937, were susceptible to non-transduced T-cell cytotoxicity, potentially confounding CAR-T functional assays and overestimating CAR-T activity in vitro. The examined parameters were integrated into a scoring framework to rank AML cell lines according to their suitability for in vitro CAR-T studies. Based on this framework and additional assay-related considerations, OCI-AML2, OCI-AML5, MV4-11, and MOLM-13 were identified as most suitable for in vitro evaluation of CAR-T products, particularly those targeting CD33 and CLL1. These findings may facilitate more informed selection of AML cell lines for preclinical development of CAR-T therapies for AML.",
  "abstract_shown": true,
  "affiliations": [
    "Center for Precision Genetic Technologies for Medicine, National Medical Research Center for Hematology, Moscow 125167, Russia",
    "National Medical Research Center for Hematology, Moscow 125167, Russia"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Vassa D. Davydova",
      "orcid": "0009-0005-9983-3225"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Anastasia A. Zotova"
    },
    {
      "affs": [
        1
      ],
      "name": "Nikolay M. Kapranov"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Dmitry V. Dianov",
      "orcid": "0000-0002-2687-8482"
    },
    {
      "affs": [
        1
      ],
      "name": "Yulia O. Davydova"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Tatiana A. Nenasheva",
      "orcid": "0000-0002-1669-5244"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Irina Y. Zaichenko",
      "orcid": "0000-0001-5063-3111"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Sergei D. Losev"
    },
    {
      "affs": [
        1
      ],
      "name": "Kseniia A. Nikiforova"
    },
    {
      "affs": [
        1
      ],
      "name": "Irina V. Galtseva"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Apollinariya V. Bogolyubova",
      "orcid": "0000-0002-8664-6341"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/9tyab495838yk.bib",
  "cited_by": 0,
  "doi": "10.3390/cells15211964",
  "fulltext_url": null,
  "id": "9tyab495838yk",
  "issns": [
    "2073-4409"
  ],
  "landing_url": "https://www.mdpi.com/2073-4409/15/21/1964",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|CAR-T cell therapy research"
    ]
  ],
  "openalex": "W7224119457",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-28",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/9tyab495838yk.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:02Z",
      "native_id": "10.3390/cells15211964",
      "source": "crossref",
      "url": "https://www.mdpi.com/2073-4409/15/21/1964"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|CAR-T cell therapy research",
      "subfield": "oncology"
    }
  ],
  "title": "Systematic Characterization of AML Cell Lines to Support Preclinical In Vitro CAR-T Research",
  "title_text": "Systematic Characterization of AML Cell Lines to Support Preclinical In Vitro CAR-T Research",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:02Z",
  "url": "https://research.draconitic.com/paper/9tyab495838yk",
  "venue": "Cells",
  "versions": []
}